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Background: In the rituximab era, the conventional International Prognostic index (IPI) lost at least in part its predictive
power, while the National Comprehensive Cancer Network-IPI (NCCN-IPI) seems to be a new and valid prognosticator.
However, it has not yet been evaluated in patients with localized disease and it has not been compared with the modiﬁed
IPI (mIPI) of the pre-rituximab era. In order to evaluate the different prognosticators and to assess the importance of rituxi-
mab and radiotherapy (RT), we carried out the so far largest retrospective analysis of patients with localized diffuse large
B-cell lymphoma (DLBCL).
Patients and methods: We retrospectively assessed clinical and therapeutical data of 1405 patients treated in from
1987 to 2012 in 10 cancer centers in Italy and 1 in Austria.
Results: All patients underwent an anthracycline containing polychemotherapy and 254 additional rituximab.
The median follow-up was 5.7 years (range 0.1–23 years). The 5-year overall survival (OS) was 75%, being signiﬁcantly
superior in those who underwent additional rituximab, while RT consolidation did not improve the outcome of those
who received immunochemotherapy. Patients with extranodal disease beneﬁted from the addition of rituximab, while RT
did not improve OS of the immunochemotherapy subgroup. In the pre-rituximab era, the mIPI showed a better perform-
ance than the others. In rituximab-treated patients, the NCCN-IPI had the highest discriminant value and the 5-years OS
varied signiﬁcantly (P < 0.001) between the three risk groups and was 98% in low-risk patients, 82% in those with a low-
intermediate risk and 57% among high-intermediate and high-risk cases.
Conclusions: The NCCN-IPI is so far the best prognosticator for patients with localized DLBCL who underwent
R-CHOP(-like). The addition of rituximab is indispensable regardless of the risk category and site of involvement, while the
addition of RT should be reserved to those cases who are ineligible to rituximab.
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introduction
Diffuse large B-cell lymphoma (DLBCL) is an aggressive but po-
tentially curable group of non-Hodgkin lymphomas accounting
for ∼30% of newly diagnosed cases [1]. The clinical course is
heterogeneous and, while some patients after several treatment
lines eventually die of the disease, others achieve an early com-
plete remission and never relapse. Research regarding risk-
adapted therapies for this neoplasia is still at the beginnings but
new, targeted therapies are underway. Therefore, clinicians need
easily applicable prognostic parameters to predict these patients’
clinical course, especially since new molecular markers have not
yet entered the clinical routine.
Up to now, the International Prognostic index (IPI) has
proven to be the most important score for predicting the
patient’s clinical course and has been the gold standard for >20
years [2]. However, in clinical routine as well as in clinical trials,
it might not be an optimal tool for stage I/II patients since they
cannot have ≥2 involved extranodal sites, and the negative
impact of stage II disease might be underestimated. Therefore,
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Miller et al. [3] proposed the stage-modiﬁed IPI (mIPI) for
DLBCL patients for whom chemotherapy, according to the CHOP
regimen (cyclophosphamide, doxorubicin, vincristine and pred-
nisone), with or without radiotherapy (RT), was planned. It
proved to be a strong prognosticator but it was never validated
in a population-based analysis. After the introduction of rituxi-
mab, Persky et al. [4] applied the mIPI to a study cohort who
underwent R-CHOP with or without RT, but they did not evalu-
ate explicitly its strength to discriminate between patients with
different prognoses. Only recently, Zhou et al. [5] published a
revised version of the IPI, namely the National Comprehensive
Cancer Network-IPI (NCCN-IPI), for DLBCL patients treated
in the rituximab era and again only stage III/IV disease was con-
sidered as a bad prognosticator, while the number of affected
extranodal sites were not classiﬁed as a poor prognostic factor
but only certain extranodal localizations. This revision was ne-
cessary since the introduction of rituximab reduced the discrim-
inatory power of the IPI, especially in patients with a high-risk
disease [6, 7]. Again, patients with stage I/II disease were not
evaluated separately.
Herein, we present the ﬁrst population-based validation of the
prognostic power of the IPI, the mIPI and the NCCN-IPI in
stage I/II DLBCL patients who underwent in ﬁrst line a CHOP
or CHOP-like chemotherapy with or without rituximab or RT.
patients andmethods
study population
From 1987 to 2012, 10 cancer centers in Italy and 1 in Austria retrospectively
collected clinical and therapeutic data from 1405 consecutive patients
affected by stage I/II DLBCL. The histologic diagnosis was carried out
according to the 2001 [8] and 2008 [9] WHO classiﬁcations and, therefore,
histologic specimens of cases assessed before 2001 were reviewed by local
specialists in lymphoma diagnosis. Staging included, in all cases, bone
marrow biopsy in order to exclude stage IV disease as well as a whole-body
imaging. At time of diagnosis all IPI parameters (age, lactate dehydrogenase
levels (LDH), performance status, stage, number and localization of extrano-
dal sites) were assessed. The mIPI was calculated as proposed by Miller et al.,
[3] while the NCCN-IPI was calculated according to Zhou et al. [5]. The
CHOP(-like) [10] group consisted of 1151 patients who underwent a median
of four cycles (range 2–8 cycles) of chemotherapy followed by RT in 523
cases (45%). The remaining 254 patients underwent a median of six cycles of
R-CHOP(-like) (range 1–10 cycles) with additional RT in 115 cases (45%).
Clinical characteristics assessed at time of diagnosis are summarized in the
supplementary Table, available at Annals of Oncology online. This study was
carried out following the principles of the Helsinki declaration and was
approved by the institutional review board of Bolzano, Italy.
statistical analysis
The primary end point of this analysis was overall survival (OS), deﬁned as
the time from diagnosis of DLBCL until death from any cause, or date of last
follow-up for censored patients [11]. OS was calculated by the Kaplan–Meier
method; survival curves were compared using the log-rank test. A Cox pro-
portional hazards (PH) model was used to estimate the hazard ratio (HR)
and its conﬁdence interval at 95% (95% CI), with the low-risk group as the
reference group. Univariate and multivariate analyses were carried out by
means of Cox PH regression. Continuous biologic covariates were dichoto-
mized according to usual clinical thresholds and the χ2 test or Fisher’s exact
test was used to compare categorical variables. Since this is an observational,
retrospective and multicenter study, a sample size was not planned. The per-
formance of the different prognostic scores (IPI, mIPI and NCCN-IPI) were
checked graphically by the Kaplan–Meier curves and analytically by means
of the HRs and discriminating power, expressed as c-Harrell [12] and
explained variation (R2, as deﬁned by Royston) [13]. The c-Harrel and R2
standard error and 95% CI were estimated by means of 250 bootstrap re-
samples. We compared all three scores (IPI, mIPI, NCCN-IPI) for patients
who underwent a CHOP(-like) chemotherapy with or without rituximab.
All carried out tests were two sided.
results
overall outcome
Overall, the median follow-up was 5.7 years (range 0.1–23
years), varying from 6.2 years (range 0.1–23 years) in the pre-
rituximab cohort (n = 1151, 82%) to 4.6 years (range 0.1–12
years) in those patients who underwent immunochemotherapy
(n = 254, 18%). The actual number of patients for each of the
prognostic index is shown in Table 1. The 5-year OS was 75%
(95% CI 73% to 78%) for all 1405 patients, being signiﬁcantly
superior in those who underwent additional rituximab (85%,
95% CI 80% to 89%) compared with the remaining ones who
did not (73%, 95% CI 70% to 76%; P < 0.001).
pre-rituximab era
We evaluated the impact of all prognostic factors contributing
to one of the evaluated scores regarding their impact on OS.
They all proved to be strong prognosticators for OS (Table 2).
Also, all three scores were strong predictors for OS (Table 2 and
Figure 1). However, in the pre-rituximab era, the mIPI showed a
better performance by allocating 15% of patients in the high-
risk group (compared with 2% by the IPI and 5% by the NCCN-
IPI) with a c-Harrell of 64.0 (59.9 for IPI and 61.3 for NCCN-
IPI).
rituximab era
The impact of all prognostic factors contributing to one of the
evaluated scores regarding their impact on OS is listed in
Table 2. Also, for patients treated with additional rituximab, IPI,
mIPI and NCCN-IPI proved prognostic ability (Table 2 and
Figure 2). However, intermediate- and high-risk groups of the
mIPI tend to overlap (HR 1.50, P = 0.260). Instead, IPI and
NCCN-IPI segregated the cohort in three well-separated risk
groups but the IPI allocated 5% of patients to the high-risk
group while the NCCN-IPI assigned 12% to it. Overall, NCCN-
IPI showed better performances than the other prognostic
scores, with the highest discriminant value in terms of c-Harrell
(75.2 versus 69.8 and 73.4 for IPI and mIPI, respectively) and
explained variation R2 (49.7% versus 36.7% and 35.9% for IPI
and mIPI, respectively). When considering stage II disease as a
negative prognosticator instead of stage III/IV as in the mIPI,
the discriminatory power of the NCCN-IPI did not improve
(data not shown).
comparison of treatment modalities
Due to the large number of assessed patients, we compared the
OS according to the addition of rituximab and RT (Figure 3).
Patients who underwent both rituximab and RT had a superior
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OS when compared with all the others. However, RT consolida-
tion improved OS signiﬁcantly only in those patients who
underwent sole chemotherapy (P < 0.001) while it did not inﬂu-
ence the survival of cases treated with additional rituximab
(P = 0.216). Among the latter, survival curves were even overlap-
ping in the NCCN-IPI 0-1 group (P = 0.778; Figure 4) but also
cases with an NCCN-IPI of 2–3 (P = 0.507) and 4–6 (P = 0.243)
did not proﬁt from RT.
When analyzed separately, patients with or without extrano-
dal disease and an NCCN-IPI of 0-1 had a signiﬁcant survival
beneﬁt when rituximab was added to standard therapy
(P = 0.007 and P = 0.040). Instead, while in patients with extra-
nodal disease who underwent only chemotherapy, the addition
of RT lead to a survival beneﬁt (P = 0.003), this was not the case
for immunochemotherapy-treated patients (P = 0.820).
discussion
Herein, in the ﬁrst population-based validation of the prognostic
power of the IPI, the mIPI and the NCCN-IPI in stage I/II
DLBCL patients who underwent in ﬁrst line a R+/−CHOP or
CHOP-like chemotherapy regimen with or without RT, we
provide evidence that the new NCCN-IPI is the best available
Clinical Prognostic index for patients with localized disease.
Moreover, rituximab has changed the clinical course of this neo-
plasia in patients with localized disease as well and, therefore,
immunochemotherapy should also be considered as the stand-
ard of care for patients with localized DLBCL, while RT should
be reserved for those patients in whom rituximab is contraindi-
cated.
In the pre-rituximab era, the mIPI, proposed more than 15
years ago [3], proved to be the best prognosticator for OS. This
could be in part explained by the important survival difference
between stage I and stage II patients which we also conﬁrmed in
the present analysis and was not considered in the conventional
IPI. However, since up to now almost all patients undergo
immunochemotherapy consisting of an anthracycline-contain-
ing chemotherapy regimen associated with rituximab with or
without RT the mIPI has become obsolete. Furthermore, rituxi-
mab completely changed the clinical course of patients with
DLBCL [14], so the discriminatory power of the IPI is reduced
for both those patients with advanced stage disease [6, 7] and
for those with localized disease, as shown in the present analysis.
For the former, the NCCN-IPI was assessed in an independent
evaluation set, while the current study analyzed its discrimin-
atory power for the latter and ascertained that the NCCN-IPI
had the highest discriminant value in terms of c-Harrell and
explained R2 variation. When considering stage II disease as a
negative prognosticator instead of stage III/IV, as in the mIPI,
the discriminatory power of the NCCN-IPI did not improve.
Therefore, the NCCN-IPI can also be applied to patients with
localized DLBCL without the necessity for modiﬁcations as was
the case in the pre-rituximab era [3].
Due to the higher discriminatory power of the NCCN-IPI
localized DLBCL, it might be possible to identify a subgroup
which does not beneﬁt from the association of all three treat-
ment modalities therefore a comparison of the outcome of
patients with an NCCN-IPI of 0-1 according to the addition of
rituximab and RT was carried out. As expected, and in line with
the SWOG 0014 study [4], the addition of rituximab improved
OS substantially. On the other hand, RT consolidation seems to
be questionable in patients who underwent immunochemother-
apy. This is also valid for patients with extranodal disease. In the
past, some study protocols considered extranodal disease in
DLBCL as an indication for RT regardless of the presence of
bulky disease [15, 16]. Therefore, prospective trials conﬁrming
the data of the current analysis are needed, since the omission of
RT consolidation would reduce the risk of treatment-related
toxicity. Indeed, the German UNFOLDER trial (NCT00278408)
is currently evaluating the impact of RT on patients with bulky
Table 1. Actual number of patients in each of the three risk groups for each of the prognostic indices
Factor No rituximab Rituximab Total Missing
N n (%) N n (%) N % P-value N (%)
IPI
1151 254 1405 –
0–1 936 (81) 188 (74) 1124 (80) 0.014
2 186 (16) 53 (21) 239 (17)
3 29 (2) 13 (5) 42 (3)
mIPI
1151 254 1405 –
0–1 690 (60) 127 (50) 817 (58) 0.013
2 292 (25) 78 (31) 370 (26)
3–4 169 (15) 49 (19) 218 (16)
NCCN-IPIa
905 234 1139 266 (19)
0–1 385 (42) 88 (38) 473 (41) 0.004
2–3 472 (52) 119 (51) 591 (52)
4–6 48 (5) 27 (11) 75 (4)
aOnly one patients had score of 6.
 | Mian et al. Volume 25 | No. 12 | December 2014
original articles Annals of Oncology
 at U
niversitÃ degli Studi di M
odenae Reggio Emilia on December 9, 2015
http://annonc.oxfordjournals.org/
D
ow
nloaded from
 
Table 2. Impact of the single IPI/NCCN-IPI factors and the three analyzed prognostic indices (IPI, mIPI, NCCN-IPI) on overall survival in univariate
analysis
Without rituximab With rituximab
HR 95% CI P HR 95% CI P
Age 60+ years 1.83 1.47–2.28 <0.001 4.36 1.91–9.97 <0.001
Age (years)a
≤40 1.00 1.00
41–60 1.46 1.01–2.12 0.042 8.37 0.44–161a 0.159
61–75 2.20 1.54–3.15 <0.001 18.6 1.03–336a 0.047
>75 3.85 2.40–6.17 <0.001 42.5 2.34–770a 0.011
LDH > UNL 2.18 1.74–2.73 <0.001 2.71 1.41–5.21 0.003
LDH
Normal 1.00 1.00
>1–3 UNL 2.26 1.76–2.90 <0.001 2.70 1.35–5.41 0.005
>3 UNL 2.77 1.60–4.80 <0.001 4.97 1.14–21.6 0.033
PS >1 2.32 1.75–3.07 <0.001 3.43 1.73–6.77 <0.001
Stage II 2.01 1.59–2.54 <0.001 2.25 1.06–4.78 0.035
Male gender 0.99 0.79–1.23 0.913 1.50 0.75–3.01 0.248
RT 0.58 0.45–0.73 <0.001 0.64 0.32–1.26 0.197
IPI
0–1 1.00 1.00
2 2.51 1.95–3.23 <0.001 2.49 1.16–5.31 0.019
3 4.34 2.71–6.94 <0.001 12.3 5.21–28.5 <0.001
mIPI
0–1 1.00 1.00
2 2.14 1.65–2.78 <0.001 6.04 2.20–16.5 0.001
3–4 3.54 2.69–4.65 <0.001 9.08 3.30–25.0 <0.001
NCCN-IPI
0–1 1.00 1.00
2–3 2.02 1.54–2.65 <0.001 8.17 1.91–34.9 0.005
4–6 5.82 3.87–8.75 <0.001 31.4 6.98–141 <0.001
NCCN-IPI available in 905 cases treated without rituximab and 234 treated with rituximab.
aSince in the group of patients with age ≤40 no events were observed leading to a complete separation of events, the Firth’s penalized likelihood Cox
regression analysis was applied.
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Figure 1. Overall survival according to IPI (A), mIPI (B) and NCCN-IPI (C) in patients who underwent a CHOP/CHOP-like regimen in ﬁrst line.
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and/or extranodal disease who undergo rituximab and CHOP.
Overall, the NCCN-IPI is more complex than the conventional
IPI but it seems to better weigh the impact of age, LDH and
extranodal disease. Moreover, in contrast with the IPI, no ad-
justment of the scoring system for localized DLBCL is necessary
since the attempt to consider stage II disease instead of stage
III/IV as a poor prognosticator did not improve the discrimin-
atory power.
In 2010, Gutirérrez-García et al. [17] compared the survival
differences of patients with nodal and extranodal disease accord-
ing to the addition of rituximab to standard chemotherapy. They
concluded that immunochemotherapy signiﬁcantly prolonged
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OS by RT and rituximab (n = 1405)
Group N % 5-yrs OS% (CI95) HR CI95 P
Without ritux –RT 628 45 68 (64–72) 1.00 
Without ritux +RT 523 37 79 (75–82) 0.61 0.48–0.76 <0.001
With ritux –RT 139 10 82 (74–88) 0.50 0.32–0.77 0.002
With ritux +RT 115 8 89 (81–94) 0.32 0.18–0.57 <0.001
Total 1405
Figure 3. Overall survival according to rituximab administration and RT in the whole cohort (A: Graph; B: Analysis of signiﬁcance ). RT, radiotherapy.
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Figure 2. Overall survival according to IPI (A), mIPI (B) and NCCN-IPI (C) in patients who underwent a R-CHOP/R-CHOP-like regimen in ﬁrst line.
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survival of patients with nodal DLBCL while it did not in those
with extranodal disease. In the cohort used for this study, this
was not the case since all patients had a better OS regardless of
the site of disease. Moreover, while in the pre-rituximab era RT
consolidation improved the survival of patients with extranodal
disease, nowadays it seems to be no longer necessary.
Despite the expected limitations of a retrospective analysis,
the large number of cases, the long follow-up time and the
homogeneity of selected patients according to stage and histo-
type all gave reliability to our results. A central pathology review
was not carried out. However, all participating centers have ex-
tensive experience in lymphoma diagnosis and management,
with the active involvement of hemopathology specialists. Since
rituximab has entered the clinical routine around the year 2000,
the follow-up time between the chemotherapy and immuno-
chemotherapy group were different. However, the hazard func-
tion of survival reached its maximum around 12–24 months
after diagnosis and tended to reach a plateau after around
60 months why in both groups most of the expected events were
registered.
In conclusion, the NCCN-IPI is the best prognosticator for
patients with localized DLBCL who undergo anthracycline-con-
taining chemotherapy in association with rituximab since it has
the best discriminating power. Therefore, with the arrival of new
and risk-adapted treatment strategies, it might be helpful for
clinical decision taking. The addition of rituximab is indispens-
able regardless of the risk category and site of involvement,
while RT consolidation is questionable and should be reserved
to those cases who are ineligible to rituximab. These results
need to be evaluated in prospective trials.
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Background: Cognitive impairment and fatigue have been associated with cancer and its treatment. We present base-
line data from a large longitudinal study that evaluates cognitive function, fatigue, and potential underlying mechanisms
following diagnosis of colorectal cancer (CRC).
Patients and methods: We evaluated CRC patients with stage I–III disease before or after surgery, participants with
limited metastatic disease and healthy controls (HC). Neuropsychological evaluation included clinical and computerised
tests. Participants completed questionnaires for fatigue and quality of life (QOL)-(FACT-F), anxiety/depression, and cognitive
symptoms (FACT-Cog). Ten cytokines, clotting factors, sex hormones, carcinoembryonic antigen (CEA), and apolipoprotein
E genotype were evaluated. Primary end points were cognitive function on clinical tests evaluated by a Global Deﬁcit score
(GDS) and fatigue. Associations between test results, demographic, and disease related factors were explored.
Results:We assessed 291 participants with early-stage disease [median age 59 (23–75) years, 63% men], 72 with meta-
static disease, and 72 HC. Using GDS, 45% (126/281) of participants with early-stage CRC had cognitive impairment
versus 15% (11/72) of HC (odds ratio 4.51, 95% conﬁdence interval 2.28–8.93; P < 0.001), with complex processing
speed, attention/working memory, and verbal learning efﬁciency being most affected. Women with early-stage CRC had
greater cognitive impairment than men [55/105 (52%) versus 71/176 (40%), P < 0.050]. Cognitive symptoms were self-
reported by 21% (59/286) of early-stage patients versus 17% (12/72) of HC; fatigue by 52% (149/287) of early-stage
patients and 26% (19/72) of HC (P < 0.0001). Women reported more fatigue than men (P = 0.003). Fatigue, QOL, anxiety/
depression, and cognitive symptoms were associated with each other (r = 0.43–0.71), but not with neuropsychological per-
formance. Most cytokines were elevated in cancer patients. Cognitive function was not associated with cytokines, sex hor-
mones, clotting factors, CEA, or apolipoprotein E genotype.
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